Ethionamide shortage — GR supply status & alternatives

Ethionamide

ATC J04AD03

In supply · Australia

In supply · 🇦🇺 Australia · short in🇺🇸 US🇬🇷 GR

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Controlled substance
Active ingredient (INN)	Ethionamide
ATC level 5	J04AD03
ATC level 4	J04AD
Therapeutic category	Auto-created by U.S. Food and Drug Administration — Drug Shortages scraper

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

How long have past shortages lasted? from 1 resolved event

◷

~1 month

Historical pattern from resolved shortage records — not a prediction of this event.

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

4 API manufacturers

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Moderate concentration risk✓ 2 WHO-prequalified

Orgapharm SasPen Tsao Chemical Industry LtdMicro Labs LimitedApichem Laboratories Private LTD

Manufacturing countries: France, India · Source: FDA List of Drug Master Files

Shortage status by regulator official notices

🇺🇸

United States

FDA · 1h ago

Medium

🇬🇷

EOF · 1d ago

Medium

Verified timeline regulator events

🇬🇷 4 May 2026

medium reported

🇬🇷 2 Feb 2026

Shortage resolved

🇺🇸 16 July 2025

medium reported

🇺🇸 16 July 2025

medium reported

Sources official regulators

🇺🇸

FDA

verified 1h ago

verify ↗

🇬🇷

EOF

verified 1d ago

verify ↗

Mederti Drug Report

Generated 6 July 2026 · Australia market · 2 regulatory sources

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.